News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
atulya keratin & wheat protein shampoo has force of natural ingredients like extract of wheat, fenugreek, reetha & almond oil
Subscribe To Our Newsletter & Stay Updated
